Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

Background CD8+ T cells are a highly diverse population of cells with distinct phenotypic functions that can influence immunotherapy outcomes. Further insights on the roles of CD8+ specificities and TCR avidity of naturally arising tumor-specific T cells, where both high and low avidity T cells reco...

Full description

Bibliographic Details
Main Authors: Eileen E Parkes, EDWARD JAMES, Doreen Lau, Gessa Sugiyarto, Samuel Luke Hill, David Arcia-Anaya, Denise S M Boulanger, Tim Elliott
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/8/e007114.full

Internet

https://jitc.bmj.com/content/11/8/e007114.full

Similar Items